Pharma Two B Expands List of Clinical Sites Enrolling for Phase IIb Study of P2B001 for PD to 25

Jul 02, 2014, 07:30 ET from Pharma Two B

REHOVOT, Israel, July 2, 2014 /PRNewswire/ --

Pharma Two B announced today that the company's ongoing Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease is now enrolling qualifying patients at 25 clinical sites throughout the US and Israel.  Study details, site locations and contact people can be found here.

The study, titled A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease, will enroll a total of 150 patients.

"Twenty-six patients are currently enrolled in the study. We expect the pace of recruitment to substantially increase with a new total of 25 clinical sites actively enrolling," said Pharma Two B CEO Dr. Nurit Livnah.  "We are confident that P2B001 is on the right track and look forward to seeing the results of this very important study in the coming months."

"Patients and the pharmaceutical industry alike are proactively looking to find new and improved solutions for Parkinson's disease. A few years ago, Pharma Two B identified the low-dosage-treatments niche.  Subsequently, the company has been diligently executing an ambitious development plan and meeting all targets.  We are already planning the Phase III study of P2B001 as well as determining the fastest way to successfully bring this product to market," said chairman of the board of Pharma Two B Mr. Ehud Marom.

About Pharma Two B 

Pharma Two B is a drug discovery company in Israel, developing innovative products, with clinical and commercial added value, based on previously approved drugs. The company develops synergistic combinations of two drugs, acting in complementary biological mechanisms that enable the use of unique low doses, while maintaining high therapeutic benefit. The company also has a line of select generic products in new formulations. To date, Pharma Two B has completed the development and licensing out of five generic products. The company has a very experienced and dedicated management team, with both generic and innovative drug development experience. The company's chairman of the board, Mr. Ehud Marom, is credited with successfully bringing several new drugs to Phase III. He is also well known for his contribution to the successful launching of LCM and for running the global operations of the market launch of Copaxone for MS. The company's CEO is Dr. Nurit Livnah. She previously served as the V.P. of R&D at several innovative drug development companies in Israel.

Press Contact:
Marjie Hadad
MH Communications

SOURCE Pharma Two B